Derkach K V, Bondareva V M, Shpakov A O
I.M.Sechenov Institute of Evolutionary Physiology and Biochemistry, RAS, 44, Toreza pr., St. Petersburg, 194223, Russian Federation;
Adv Gerontol. 2017;30(6):851-858.
The C-peptide, the product of proinsulin proteolysis, not only is a signal molecule, but also, forming a complex with insulin, is able to modulate the signaling functions of insulin. The signaling systems sensitive to insulin in the hypothalamus and other brain areas are among the targets of insulin. We hypothesized that in systemic deficiency of insulin and C-peptide in the type 1 diabetes mellitus (DM) and in severe forms of the type 2 DM, the increase in the level of C-peptide in the CNS will improve central effects of insulin, including its influence on peripheral metabolism. To verify this, the influence of separate and co-administration of intranasal insulin (II) and C-peptide (IP) on their metabolic parameters and sensitivity to insulin in rats with acute and mild type 1 DM induced by the treatment with streptozotocin at the doses of 60 and 35 mg/kg and in rats with neonatal type 2 DM corresponding to severe long-term form of type 2 DM in human was studied. The treatment of animals with II and IP was carried out for 7 days in the daily doses of 20 and 10 μg/rat, respectively. The co-administration of II and IP leading to an increase of insulin and C-peptide levels in the brain was most effective. In rats with type 1 DM treated with the combination of II plus IP, hyperglycemia was decreased and weight loss was prevented. In rats with type 2 DM, co-administration of II and IP led to the normalization of glucose homeostasis and the increase in insulin sensitivity, as shown by glucose-tolerance and insulin-glucose tolerance tests, and to improvement of lipid metabolism, as demonstrated by the decrease in the atherogenic index. The effectiveness of monotherapy with II was lower than in the case of a combination of II+IP, while monotherapy with C-peptide had little effect on the indicators studied. Thus, the simultaneous increase of insulin and C-peptide levels in the brain in the conditions of their deficiency in diabetic pathology can be considered as one of the promising approaches to restore the central insulin-dependent regulation of peripheral metabolism and to improve the utilization of glucose in different forms of DM.
胰岛素原蛋白水解产物C肽不仅是一种信号分子,而且与胰岛素形成复合物后,能够调节胰岛素的信号传导功能。下丘脑和其他脑区中对胰岛素敏感的信号系统是胰岛素的作用靶点之一。我们推测,在1型糖尿病(DM)以及严重的2型糖尿病中,胰岛素和C肽出现全身性缺乏时,中枢神经系统(CNS)中C肽水平的升高将改善胰岛素的中枢效应,包括其对周围代谢的影响。为了验证这一点,我们研究了分别给予和联合给予鼻内胰岛素(II)和C肽(IP)对链脲佐菌素以60和35 mg/kg剂量处理诱导的急性和轻度1型糖尿病大鼠以及对应于人类严重长期2型糖尿病的新生2型糖尿病大鼠的代谢参数和胰岛素敏感性的影响。分别以20和10 μg/大鼠的日剂量对动物进行II和IP处理,持续7天。联合给予II和IP导致脑中胰岛素和C肽水平升高,效果最为显著。在接受II加IP联合治疗的1型糖尿病大鼠中,高血糖症减轻,体重减轻得到预防。在2型糖尿病大鼠中,联合给予II和IP导致葡萄糖稳态正常化,胰岛素敏感性增加(通过葡萄糖耐量和胰岛素-葡萄糖耐量试验表明),并且脂质代谢改善(通过动脉粥样硬化指数降低证明)。II单一疗法的效果低于II + IP联合疗法,而C肽单一疗法对所研究的指标几乎没有影响。因此,在糖尿病病理状态下其缺乏的情况下,同时提高脑中胰岛素和C肽水平可被视为恢复外周代谢的中枢胰岛素依赖性调节以及改善不同类型糖尿病中葡萄糖利用的有前景的方法之一。